Cardiovascular

INDICATION

1. Adult patients with primary hyperlipidemia and mixed dyslipideima as an adjuvant diet to reduce elevated total -C, LDL -C, ApoB, non HDL - C, and TG levels and to increase HDL - C levels.
2. Pediatric patients 8 to 17 years of age with heterozygous familiar hypercholesterolemia to reduce elevated total - C, LDL -C and ApoB after failing adequate trail of diet therapy.
3. Pediatric patients 7 to 17 years of age with homozygous familiar hypercholesterolemia to reduce LDL -C, total - C, non HDL - C and Apo B as an adjuvant to diet either alone or with other lipid lowering treatments.
4. Adult patients with hypertriglycerdemia as an adjuvant to diet, Adult patient with primary dysbetalipoprotinemia as an adjuvant to diet, Adult patient with homozygous familiar hypercholesterolemia to reduce LDL - C, total C and ApoB.
5. Slowing the progress of atherosclerosis as part of a treatment strategy to lower total - C and LDL - C as an adjuvant to diet, Risk reduction of MI , Stroke and aterial revascularization procedures in patient without clinically evident CHD but with multiple risk factorsy.